Communication Science Against Antibiotic Resistance’s Post

"Infections are the second-leading cause of death among cancer patients, and lead to one in five being hospitalised during treatment. Given that many cancer therapies weaken the immune system, making patients more susceptible to infections, this is to some extent to be expected. But increasingly clinicians see infections that are becoming drug-resistant — antibiotics once effective against them no longer work. Without new and effective antibiotics, this is only going to get worse, with more people surviving cancer only to die of an infection that was previously treatable." Global Antibiotic R&D Partnership (GARDP) World Anti-Microbial Resistance Congress  https://lnkd.in/e_uFVFUA

Considerable progress has been made in the field of cancer over the last few decades, marked by significant advancements. Unfortunately, the escalating menace of drug-resistant bacteria poses a substantial challenge, undermining the progress in cancer treatment. People with cancer face a higher vulnerability to infections as their immune defenses are compromised. Surgical procedures and treatments create immense pressure on the immune system, increasing the susceptibility to infections. Read more ➡ https://lnkd.in/dP-ynr6c #amr #cancer #antimicrobialresistance #antibioticresistance

Infections pose a significant threat to cancer patients. As we celebrate higher cancer survival rates, the shadow of antimicrobial resistance looms large, threatening to reverse these gains. The urgent need for new, effective antibiotics is clear; without them, the risk of dying from previously treatable infections will rise. The focus on high-cost cancer drugs may inadvertently shift attention and investment away from essential antibiotics, crucial for many cancer patients' survival. Balancing investment in cancer treatment with the development of new antibiotics is not just vital for patient care—it's an economic imperative. Ensuring we have robust defenses against infections is as crucial as advancing cancer care itself. https://lnkd.in/eWPCHwXY

📣 Check out our Executive Director, Manica Balasegaram's insightful article on the growing threat of antibiotic resistance for cancer patients, in the Financial Times. 🌍💊 Don't miss this important read on the global challenge we're tackling everyday! 📰✨ #GARDP #AntibioticResistance #Healthcare #ReadNow

ASCP Daily Diagnosis 05/30 CST Patients with cancer receiving posaconazole for invasive fungal infections who had albumin levels at or below 3 g/dL were at increased risk for subtherapeutic levels of the medication. A higher initial dosing strategy and therapeutic drug monitoring for oncology patients with albumin ≥3 g/dL receiving posaconazole particularly for the treatment of invasive fungal infection could be considered. https://lnkd.in/gCVMmcMK

Methotrexate is a medication that is used to treat a variety of conditions, including cancer and autoimmune diseases. It belongs to a class of drugs called antimetabolites, which interfere with the growth of certain cells in the body. The mechanism of action of methotrexate involves its ability to inhibit the enzyme dihydrofolate reductase (DHFR). This enzyme is involved in the synthesis of tetrahydrofolate, which is essential for the synthesis of DNA, RNA, and proteins. By inhibiting DHFR, methotrexate disrupts the production of these essential molecules, particularly in rapidly dividing cells such as cancer cells and cells involved in the immune response. In cancer treatment, methotrexate's ability to interfere with DNA and RNA synthesis disrupts the growth and replication of cancer cells, ultimately leading to their death. In autoimmune diseases like rheumatoid arthritis, methotrexate's effects on the immune system help to reduce inflammation and the activity of the immune cells that attack healthy tissues. Methotrexate is available in various forms, including oral tablets, injectable solutions, and as part of chemotherapy regimens for cancer treatment. It is important to use methotrexate only as prescribed by a healthcare professional, as it can have serious side effects if not used properly. Regular monitoring of blood counts and liver function is often required during methotrexate treatment to ensure its safety and effectiveness. We are GMP manufactuer of Methotrexate APIs in China www.scrianenapi.com #methotrexate  #APIs #antimetabolite #scarianen

𝐁𝐚𝐫𝐢𝐧𝐭𝐡𝐮𝐬 𝐁𝐢𝐨 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐬 𝐈𝐧𝐭𝐞𝐫𝐢𝐦 𝐃𝐚𝐭𝐚 𝐟𝐫𝐨𝐦 𝐏𝐡𝐚𝐬𝐞 𝟐𝐛 𝐇𝐁𝐕𝟎𝟎𝟑 𝐓𝐫𝐢𝐚𝐥 𝐚𝐧𝐝 𝐏𝐡𝐚𝐬𝐞 𝟐𝐚 𝐀𝐁-𝟕𝟐𝟗-𝟐𝟎𝟐 𝐓𝐫𝐢𝐚𝐥 𝐢𝐧 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐀𝐫𝐛𝐮𝐭𝐮𝐬 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐢𝐧 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐇𝐁𝐕 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐚𝐭 𝐀𝐀𝐒𝐋𝐃 Barinthus Biotherapeutics plc (NASDAQ: BRNS) Barinthus Biotherapeutics, formerly Vaccitech plc, presented encouraging data from two HBV clinical trials at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023. The Phase 2b trial (HBV003) evaluated VTP-300 with low-dose anti-PD-1 antibody and standard-of-care (SoC) nucleos(t)ide analogue therapy. Promising results showed meaningful HBsAg declines across all groups, especially in patients with lower baseline HBsAg levels. In the Phase 2a AB-729-202 trial, combining Arbutus Biopharma's imdusiran with VTP-300 and SoC NUC therapy, VTP-300 demonstrated a significant impact on sustaining low HBsAg levels. All participants treated with imdusiran and VTP-300 qualified to stop NUC therapy, highlighting VTP-300's potential for a functional cure. Both trials reported positive safety profiles. Notably, VTP-300 showed no treatment-related serious adverse events in combination with nivolumab, and imdusiran demonstrated consistent efficacy and safety. These findings represent a step forward in developing T cell immunotherapeutic candidates for chronic infectious diseases, autoimmunity, and cancer. #cancer #cinicaltrials #immunotherapy #chronicdisease #celltherapy #patient #treatment #oncology #therapeutics

Could GLP1 medications lower the risk of colon cancer? This retrospective study says yes Those on GLP1 meds had a 50% lower risk of colorectal cancer. Seems this is probably mostly related to weight loss and improvement and insulin resistance. Given that this is a retrospective study, it’s hard to know if this is cause and effect so further research is needed, but certainly promising American Diabetes Association #diabetes #diabetesmanagement #obesity #obesitytreatment #coloncancer https://lnkd.in/epQtAveq

Global Renal Cancer Medication Market Report 2023-2028:

Back in the summer of 2016. Falling Walls Labs (Belgrade), I was a freshman in environmental science (environmental protection with ecology to be more accurate). I spoke of (or at least I have tried to speak of, I even managed to use the microphone improperly) the potential use of plants to produce antimicrobial compounds. Both for use as pesticides and antibiotics. I spoke of two intertwined technical problems: keeping up with the evolution of resistance; and trying to preserve the plant biodiversity while utilizing plant-derived compounds. I will also add the economic and physiological aspects to this post this time. With regards to trying to keep up with the resistance, the problem should be conceptually simple. We are trying to utilize a limited number of fungi, in a limited number of bioreactors, and then there is a limited number of organic chemists that modify the preliminary antimicrobials. On the other hand, antimicrobial resistance is usually tied to plasmids (a part of the genetic material that can be transferred and often between different species, and that can be replicated without replicating the main part of the genetic material). This means that antimicrobial resistance can cross its way through the biosphere, at that point, it should be obvious that we are not doing it right, that we need to expand our search for antimicrobials outside the relatively narrow context of unicellular fungi. We need to use plants and there is already some preliminary data in traditional medicine we can use to produce antimicrobials, it is not a shot in the dark. With regards to the attempt to preserve the plant species utilized. I had advocated for the use of plant tumors (not the only, but the most promising thing I spoke of back then). We can develop hairy root tumors where applicable to gain a source of antimicrobial compounds. The "where applicable" part stands for a reason as the technique is best used on eudicots. There is also the fact that the biochemical aspects of the plant tissue can be altered, but this factor can usually be remedied. With regards to the economic aspects of such an undertaking, it leaves a lot to be desired. The new antibiotic registration undergoes very numerous regulations. Simply put, it makes antibiotic development a bad investment. Thus, the development never takes place. We should probably create something like a "right to try" for pan-resistant bacteria, as people in such situations have nothing left to lose. The hairy root economics is problematic too. Maybe we should approach the topic from a much more relaxed standpoint towards genetic engineering, as Rootec GMBH failed at trying to commercialize hairy roots without it. Since we are speaking about infections in people with cancer, we should also be wary of hormesis. We already saw in the scientific literature that some anticarcinogenic compounds (berberine, for example, which is also an antimicrobial) start increasing chemoresistance because of the hormesis.